AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
vanzacaftor 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers | 5847 | None |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
ALYFTREK is a combination of vanzacaftor, tezacaftor, and deutivacaftor that was approved for the treatment of cystic fibrosis. Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del-CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Deutivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 30, 2025 | EMA | Vertex Pharmaceuticals (Ireland) Limited | |
| Dec. 20, 2024 | FDA | Vertex Pharmaceuticals |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R07AX33 | RESPIRATORY SYSTEM OTHER RESPIRATORY SYSTEM PRODUCTS OTHER RESPIRATORY SYSTEM PRODUCTS Other respiratory system products |
Related Drugs by ATC class:
R07AX Other respiratory system products 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cystic fibrosis | indication | 190905008 | DOID:1485 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis transmembrane conductance regulator | Ion channel | PHARMACOLOGICAL CHAPERONE | UNKNOWN | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 2374124-49-7 | SECONDARY_CAS_RN |
| CHEMBL5314934 | ChEMBL_ID |
| C000731979 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4043970 | VANDF |
| C5707868 | UMLSCUI |
| CHEBI:759626 | CHEBI |
| 11971 | INN_ID |
| 2607828-37-3 | SECONDARY_CAS_RN |
| 139399801 | PUBCHEM_CID |
| 13694 | IUPHAR_LIGAND_ID |
| COM1POP492 | UNII |
| 2701431 | RXNORM |
| 45314111000001106 | SNOMEDCT_US |
| 45314211000001100 | SNOMEDCT_US |
| D12718 | KEGG_DRUG |
| 43614 | MMSL |
| d10240 | MMSL |
| 019956 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ALYFTREK | HUMAN PRESCRIPTION DRUG LABEL | 3 | 51167-121 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 33 sections |
| ALYFTREK | HUMAN PRESCRIPTION DRUG LABEL | 3 | 51167-135 | TABLET, FILM COATED | 4 mg | ORAL | NDA | 33 sections |